Grants4Apps Accelerator 2016: You imagine, Bayer supports

BayerThe Grants4Apps (G4A) Accelerator developed by Bayer invites health IT and technology startups to apply for the program's 2016 edition. This year, Bayer looks primarily into projects aimed at fostering patient-doctor feedback in the Women's Health field as well as those improving patient engagement in Cardiology, Oncology, Radiology and Ophthalmology, but Bayer is also interested in highly innovative software, hardware, technologies applied to digital health fields.

The selected 5 start-ups will get free office space for 100 days at Bayer's Pharmaceuticals headquarters in Berlin, where representatives of Bayer senior management will offer them top-level coaching. In addition, Bayer will provide a financial support of 50,000 Euro to each of the startups.

For the third year in a row, the Grants4Apps Accelerator welcomes startups from around the world, whose software services, technologies, and apps have the potential of creating value for physicians and patients. Projects can be submitted by May 31st, 2016.

"Since 2014, IT and technology passionates from all over the world, with a focus on health projects, are invited to apply for what might become their biggest development opportunity. We are more than proud of the project's echo, especially at a local level, with Bucharest being the 2nd city in overall submissions in 2015. Furthermore, Romania ranked 6th in terms of number of submissions received from all over the world, which is outstanding. We are confident that the 2016 edition will suscitate at least as much interest and local bright ideas will improve people's lives," said Ruxandra Pirojoc, Head of Communications for Bayer Romania and Bulgaria.

"At Bayer, we strongly believe in the power of the local community - Scientists, Technologists, Engineers, and Mathematicians in Bucharest, working or willing to work on projects regarding digital health and digital farming. This is why we have established a group on meetup.com, aimed at fostering innitiave and cooperation between professionals, while also serving as a networking and discussions platform. It is a local innitiave matching Bayer’s vision of open innovation and global cooperation," added George Nancu, IT Specialist at Bayer Romania.

In June, an expert jury from Bayer will select the five winners who will be invited to spend 3.5 months in the Accelerator on the Bayer Pharmaceuticals headquarters in Berlin from August to December 2016. Aside from the financial support to help developing their business, the startups will be offered free co-working space, mentoring and expert advice on business development, market research, financial planning, and pitching for investors. The goal for the startups in the program is to further develop their product and business model so they can obtain financing from other sources after the program.

Application forms for startups are available at the Grants4Apps website http://www.grants4apps.com/berlin

Bayer fully embraces new approaches of open innovation, such as the "CoLaborator" or crowdsourcing initiatives like "Grants4Targets", "Grants4Indications", "Grants4Apps" and "PartnerYourAntibodies".

Bayer: Science for a Better Life
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...